Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Dr Thibault Griseri has been awarded a Career Development Fellowship from Arthritis Research UK for his project on “Haematopoietic stem and progenitor cells as novel therapeutic targets in chronic inflammatory arthritis”.

Around 10 million people in the UK have arthritis and over 500,000 suffer from chronic inflammatory arthritis. There is yet no cure for this highly disabling and painful condition, although there are many available treatments, which help to slow down the condition. Understanding what causes the inflammation and the chronicity of some types of arthritis is key to the development of better treatments. By bringing together the fields of haematopoiesis – the formation of blood cellular components – and immunology, Dr Griseri’s project will look into how haematopoiesis inside and outside the bone marrow is influenced by inflammatory signals and how haematopoietic stem cells and progenitors cells contribute to chronicity of disease in inflammatory arthritis.

Speaking of his award, Dr Griseri says: "I am delighted and grateful to get this award because it will have a great impact in what is known about arthritis and we will be able to further develop our study of the regulation of haematopoiesis in intestinal inflammatory diseases1 to models of chronic inflammation arthritis and explore the possible crosstalk between intestinal and joint inflammation. Establishing this link will bring us closer to more advanced treatments for this condition."

Similar stories

Professor Michael Dustin appointed new Chair in Molecular Immunology

A generous gift from the Kennedy Trust for Rheumatology Research has enabled the creation of a new Chair in Molecular Immunology at the University of Oxford.

Empowering data science for single-cell analysis in Zimbabwe

An innovative computational biology training module was launched in November 2022 at the African Institute of Biomedical Science and Technology (AiBST) in Harare, Zimbabwe, where MSc students were trained in single-cell RNA sequencing data analysis.

T-cell coreceptors are well endowed—with kinases!

The kinase occupancy of CD4 and CD8 coreceptors is high, according to a new study published in PNAS.

Two prestigious Hunterian Professorships awarded to NDORMS researchers

Conrad Harrison and Tom Layton have both been awarded Hunterian Professorships for 2022 by the Royal College of Surgeons of England

Dr Alex Clarke wins Emerging Leaders Prize for lupus research

Alex is one of three exceptional lupus researchers that have been announced as winners of the Medical Research Foundation’s sixth Emerging Leaders Prize.

Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease

Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.